safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-51Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESЛекарственная гематотоксичностьDrug induced haematotoxicityПостниковС. С.PostnikovS. S.noemail@neicon.ruКостылеваМ. Н.KostylyovaM. N.noemail@neicon.ruГрацианскаяА. Н.GratsianskayaA. N.noemail@neicon.ruЕрмилинА. Е.ErmilinA. E.noemail@neicon.ruРНИМУ им. Н. И. Пирогова; РДКБРоссияPirogov Russian National Research Medical University; Central State Pediatric HospitalRussian Federation201620022018032835Copyright © Постников С.С., Костылева М.Н., Грацианская А.Н., Ермилин А.Е., 20182018Постников С.С., Костылева М.Н., Грацианская А.Н., Ермилин А.Е.Postnikov S.S., Kostylyova M.N., Gratsianskaya A.N., Ermilin A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/51

В обзоре представлены основные виды гематологических осложнений, связанных с проводимой фармакотерапией - прежде всего цитопенические синдромы, а также нарушения коагуляции. Приводятся факторы риска и механизмы развития этих нарушений. Подчеркивается важность осознания врачами существования лекарственной патологии (болезни) как отдельного вида ятрогении.

The main types of hematological complications related to ongoing pharmacotherapy - (different types of cytopenia, as well as coagulopathy) are presented. The risk factors and mechanisms of development of these disorders are discussed. The authors emphasize the importance of awareness by doctors of the existence of drug induced pathology (disease) as a separate type of iatrogeny.

лекарственная гематотоксичностьанемиялейкопениятромбоцитопениякоагулопатиячастота возникновениямеханизм действияDrug haematotoxicityanemialeucopeniathrombocytopeniacoagulopathyincidencemechanism of actionReferencesFlanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. Clin. Exp. 2008; 23: 27-41.Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. Clin. Exp. 2008; 23: 27–41.Bloom J. Principles of Hematotoxicology: Laboratory Assessment and Interpretation of Data. Toxicol Pathol March 1993; 21 (2): 130-134.Bloom J. Principles of Hematotoxicology: Laboratory Assessment and Interpretation of Data. Toxicol Pathol March 1993; 21 (2): 130–134.Анастасов А, Петров М. Лекарственные поражения крови и кроветворных органов. В кн.:Маджраков Г, Попхристов П, ред. Лекарственная болезнь. София: Медицина и физкультура; 1973. С. 307-349.Anastasov A, Petrov Ì. Drug induced haematotoxicity. In.:Madjrakov G, Pophristov P, eds. Drug disease. Sofia: Meditsina and sport; 1973. P. 307–349.Зборовский АБ, Тюренков ИН, Белоусов ЮБ. Лекарственные поражения системы крови. В кн.: Неблагоприятные побочные эффекты лекарственных средств. М.: Медицинское информационное агентство; 2008. С. 449-487.Zborovsky AB, Turenkov IN, Belousov YuB. Drug induced haematotoxicity. In.: Adverse side effects of drugs. Ìoscow: Meditsinskoe informatsionnoe agentstvo; 2008. P. 449–487.Barbaryan A, Iyinagoro C, Nwankwo № et al. Ibuprofen-Induced Hemolytic Anemia. Case Reports in Hematology 2013; Article ID 142865, 3 pages.Barbaryan A, Iyinagoro C, Nwankwo N et al. Ibuprofen-Induced Hemolytic Anemia. Case Reports in Hematology 2013; Article ID 142865, 3 pages.Marik PE, Parekh P. Life-threatening piperacillin-induced immune haemolysis in a patient with cystic fibrosis. BMJ Case Reports. 2013; 2013: bcr2012007801. doi:10.1136/bcr-2012-007801.Marik PE, Parekh P. Life-threatening piperacillin-induced immune haemolysis in a patient with cystic fibrosis. BMJ Case Reports. 2013; 2013: bcr2012007801. doi:10.1136/bcr-2012-007801.Chen F, Zhan Z. Severe drug-induced immune haemolytic anaemia due to ceftazidime. Blood Transfusion. 2014; 12 (3): 435-437. doi:10.2450/2014.0237-13.Chen F, Zhan Z. Severe drug-induced immune haemolytic anaemia due to ceftazidime. Blood Transfusion. 2014; 12 (3): 435–437. doi:10.2450/2014.0237-13.Mintzer DM, Billet SN, Chmielewsk L. Drug-Induced Hematologic Syndromes. Advances in Hematology 2009; Article ID 495863, 11 pages. doi:10.1155/2009/495863.Mintzer DM, Billet SN, Chmielewsk L. Drug-Induced Hematologic Syndromes. Advances in Hematology 2009; Article ID 495863, 11 pages. doi:10.1155/2009/495863.Ammus S. et al. Drug-induced red cell dyscrasias. Blood Reviews 1989; 3 (2): 71-82.Ammus S. et al. Drug-induced red cell dyscrasias. Blood Reviews 1989; 3 (2): 71 — 82.Li E, Ceja E, Hoffman JM. Anemias. В кн.: Tisdale JE, Miller DA, ред. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda; 2010. С. 973-87.Li E, Ceja E, Hoffman JM. Anemias. In: Tisdale JE, Miller DA, edts. Drug-induced Diseases: Prevention, Detection, and Management. Bethesdà; 2010. P. 973–87.Эритроцитарные энзимопатии. В кн.: Тащев Т, ред. Врожденные и приобретенные энзимопатии. Москва: Медицина; 1980. С. 72-90.Erythrocyte enzimopathies. In.: Taschev T, edt. Congenital and aquire enzymipathies. Moscow: Meditsina; 1980. P. 72–90.Постников СС, Галаева СС, Галаев ВС. Необычный побочный эффект азитромицина у ребенка 5 лет. Лечебное дело 2006; 3: 84-85.Postnikov SS, Galaeva SS, Galaev VS. An unusual side effect of azythromicin in 5 years child. Lechebnoe delo 2006; 3: 84–85.Plachouras, D, Giannitsioti E, Athanassia S, Kontopidou F, Papadopoulos A, Kanellakopoulou K, Giamarellou H. Clinical Infectious Diseases 2006; 43(9): e89-e91.Plachouras, D, Giannitsioti E, Athanassia S, Kontopidou F, Papadopoulos A, Kanellakopoulou K, Giamarellou H. Clinical Infectious Diseases 2006; 43(9): e89–e91.Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy 2002; 46(8): 2723-2726.Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy 2002; 46(8): 2723–2726.William В,. McNamee Jr. Resumption of Linezolid Therapy after Myelotoxicity, Clinical Infectious Diseases 2003; С. 741-742.William Â,. McNamee Jr. Resumption of Linezolid Therapy after Myelotoxicity, Clinical Infectious Diseases 2003; P. 741–742.Monson T, Schichman SA, Zent CS. Linezolid-Induced Pure Red Blood Cell Aplasia. Clinical Infectious Diseases 2002; 35 (3): e29-e31.Monson T, Schichman SA, Zent CS. Linezolid-Induced Pure Red Blood Cell Aplasia. Clinical Infectious Diseases 2002; 35 (3): e29–e31.Shukla P, Bansode FW, Singh RK. Chloramphenicol toxicity: A review. J Med Sci 2011; 2: 1313-1316.Shukla P, Bansode FW, Singh RK. Chloramphenicol toxicity: A review. J Med Sci 2011; 2:1313–1316.Гусель ВА, Маркова ИВ. Справочник педиатра по клинической фармакологии. Л.: Медицина; 1989.Gusel VA, Markova IV. Directory of pediatric clinical pharmacology. Leningrad: Meditsina; 1989.Fausel CA. Neutropenia and agranulocytosis. В кн.: Tisdale JE, Miller DA, ред. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda; 2010. С. 973-87.Fausel CA. Neutropenia and agranulocytosis. Â êí.: Tisdale JE, Miller DA, ðåä. Drug-induced Diseases: Prevention, Detection, and Management. Bethesdà; 2010. P. 973–87.Падейская ЕН. Ко-тримоксазол (бисептол). Значение в современной клинической практике и рекомендации по применению. М.: Медпрактика-М; 2003.Padeyskaya EN. Co-trymaxozol (Biseptol). The value in current clinical practice and application recommendation. Ìoscow: Medpractika-M; 2003.Белоусов ЮБ, Гуревич КГ. Нежелательные реакции со стороны системы кроветворения. В кн.: Общая и частная клиническая фармакокинетика. М.: 2006. С. 432-34.Belousov YuB, Gurevich KG. Haematopoietic system adverse reactions. In: General and private clinical pharmacokinetics. Ìoscow: 2006. P. 432–34.Jones KL, Kiel PJ. Thrombocytopenia. В кн.: Tisdale JE, Miller DA, ред. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda; 2010. С. 929-90.Jones KL, Kiel PJ. Thrombocytopenia. In.: Tisdale JE, Miller DA, edts. Drug- induced Diseases: Prevention, Detection, and Management. Bethesdà; 2010. P. 929–90.Kaufman DW, Kelly JP, Johannes CB et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82 (9): 2714-2718.Kaufman DW, Kelly JP, Johannes CB et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82 (9): 2714–2718.Young LS. Hematologic Effects of Linezolid versus Vancomycin. Clin Infect Dis 2004; 38 (8): 1065-1066.Young LS. Hematologic Effects of Linezolid versus Vancomycin. Clin Infect Dis 2004; 38 (8): 1065–1066.Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014; 42(6): 1007-1012.Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid- associated thrombocytopenia in adult patients. Infection. 2014; 42(6): 1007–1012.Papaioannides D, Bouropoulos C, Korantzopoulos Р. Co-trimoxazole induced acute thrombocytopenic purpura. Emerg Med J 2003; 20: e3.Papaioannides D, Bouropoulos C, Korantzopoulos Ð. Co-trimoxazole induced acute thrombocytopenic purpura. Emerg Med J 2003;20:e3.Hudaoglu O, Tokgöz Y. Acute Lymphoblastic Leukemia in Association with Long Term Exposure to Trimethoprim-Sulfomethaxozole. Indian pediatrics 2007; 44(4): 311-2.Hudaoglu O, Tokgöz Y. Acute Lymphoblastic Leukemia in Association with Long Term Exposure to Trimethoprim- Sulfomethaxozole. Indian pediatrics 2007; 44(4): 311–2.Garweod CL. Thromboembolic diseases». В кн.: Tisdale JE, Miller DA, ред. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda; 2010. С. 941-61.Garweod CL. Thromboembolic diseases». In: Tisdale JE, Miller DA, edts. Drug- induced Diseases: Prevention, Detection, and Management. Bethesda; 2010. P. 941–61.Насонов ЕЛ. Применение нестероидных противовоспалительных препаратов в медицине в начале 21 века. РМЖ 2003; 11 (7): 375-378.Nasonov EL. The use of non-staroidal anti-inflammatory drug in medicine in the early 21st century. RMJ 2003; 11 (7): 375–378.Сычев ДА, Раменская ГВ, Игнатьев ИВ, Кукес ВГ. Клиническая фармакогенетика: Учебное пособие. Кукес ВГ, Бочкова НП, ред. М.: ГЭОТАР-Медиа; 2007.Sychev DA, Ramenskaya GV, Ignatiev IV, Kukes VG. Clinical pharmacogenetics. Kukes VG, Bochkova NP, edts. Moscow: GEOTAR-Media; 2007.

The authors declare that there are no conflicts of interest present.